Form 4: Enliven Therapeutics Director Andrew John Phillips Acquires Stock Options

Director Andrew John Phillips acquired stock options in Enliven Therapeutics, Inc. on February 6, 2025.

Summary

• On February 6, 2025, Andrew John Phillips, a director of Enliven Therapeutics, Inc., acquired 20,491 stock options with an exercise price of $22.47.
• These options vest on the earlier of the first anniversary of the 2025 annual meeting or the date of the 2026 annual meeting, contingent upon Phillips remaining a non-employee director.
• Following the transaction, Phillips directly owns 20,491 derivative securities.

Sentiment

Score: 7

Explanation: The document indicates a standard transaction of stock options to a director, suggesting a neutral to slightly positive sentiment as it aligns the director's interests with the company's performance.

Positives

• The acquisition of stock options by a director signals confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent upon the director's continued service, aligning their interests with the company's long-term success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule, contingent on continued service, is a standard practice to incentivize long-term commitment.
• Comparable companies in the biotech industry, such as Amgen, Gilead Sciences, and Biogen, also utilize stock options as part of their director compensation.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with the company's long-term performance.

Key Dates

Keywords

stock options, Form 4, director, ELVN, Enliven Therapeutics, beneficial ownership, securities